Théa to acquire branded ophthalmics from Akorn

French ophthalmology specialist Laboratoires Théa has signed an agreement to purchase seven branded ophthalmic products from Akorn Operating Company. The transaction will make Théa a best-in-class provider of products designed to fill the needs of eye-care professionals across the USA, the company claims.

The purchase, financial terms of which were not disclose, will add seven established brands, including Akorn’s leading glaucoma therapy, Zioptan (tafluprost), to Théa’s portfolio. Théa will also welcome Akorn’s nearly 50-person sales force, which Théa expects to expand in support of anticipated growth and launches of additional products in the USA.

“The significance of this milestone purchase can be felt across our entire organization, which has been operating for 28 years and is a driving force for treatment in eye care with products available in 75 countries,” said Théa’s president, Jean-Frédéric Chibret. “As a fifth-generation member of a family that has spent more than 150 years dedicated to eye care, I’m always excited to extend Théa’s unique expertise and passion into new markets, where our goal is to improve patient quality of life by providing innovative offerings across a full range of therapeutic areas, including glaucoma, dry eye, allergy and inflammation,” he added.